NewLink's IMPRESS results disappoint

May 10, 2016 News BioVox

NewLink Genetics Corp. (NASDAQ:NLNK) sank $5.50 (33%) to $11 in early after-hours trading Monday after it said HyperAcute Pancreas algenpantucel-L missed the primary overall survival endpoint in the Phase III IMPRESS study to treat resected pancreatic cancer. Median survival among patients treated with algenpantucel-L plus standard of care (SOC) was 27.3 months vs. 30.4 months for SOC alone in the 722-patient study.

Algenpantucel-L is an allogeneic cancer vaccine containing irradiated pancreatic tumor cells modified to express 1,3-galactosyltransferase.

The company now plans to focus its efforts elsewhere in its pipeline, which includes indoleamine 2,3-dioxygenase (INDO; IDO) inhibitors indoximod (NLG8189) and GDC-0919. The company anticipates interim data next month from a Phase II study of indoximod to treat metastatic pancreatic cancer. It expects its partner, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), to report data in October from a Phase Ib study of GDC-0919 plus atezolizumab (MPDL3280A) to treat solid tumors.

Full article at BioCentury

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts